Comparative Study of Autologous Blood Injection Versus Diluted Epinephrine in Treating Actively Bleeding Gastroduodenal Ulcers
NCT ID: NCT01560702
Last Updated: 2013-09-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2012-03-31
2013-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Autologous blood
Patients will be injected by autologous blood at the edge of actively bleeding ulcer
Blood
5-20 cc autologous blood immediately withdrawn from the patient will be injected at edges of the actively bleeding ulcer.
Epinephrine injection
Patients will be injected by diluted epinephrine at the edge of actively bleeding ulcer
Epinephrine
10-30 cc of 1/10000 diluted epinephrine will be injected at edges of an actively bleeding ulcer.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Epinephrine
10-30 cc of 1/10000 diluted epinephrine will be injected at edges of an actively bleeding ulcer.
Blood
5-20 cc autologous blood immediately withdrawn from the patient will be injected at edges of the actively bleeding ulcer.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with malignancy.
* Patients with bleeding disorders or under coagulation therapy.
* Patients with known allergy to epinephrine.
16 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zagazig University
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Moahmed Hassan Emara
Lecturer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohamed H Emara, MD
Role: PRINCIPAL_INVESTIGATOR
Tropical Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, 44519, Egypt
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zagazig University Hospitals
Zagazig, Sharqia Province, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Our Department official journal
Our Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB#:278/12-3-2012
Identifier Type: -
Identifier Source: org_study_id